Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Parathyroid Gland (suis)
Brand Name
Parathyroid Cord
Generic Name
Parathyroid Gland (suis)
Active Ingredient
Sus Scrofa Parathyroid GlandCategory
Calculi Dissolution Agent [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 12 [hp_X]/mL | LIQUID | ORAL | 44911-0212 |
Detailed information about Parathyroid Cord
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Parathyroid Cord, you must consult a qualified healthcare professional.
Sus Scrofa Parathyroid Gland is a porcine-derived biological agent classified as a Calculi Dissolution Agent [EPC]. It is utilized in various clinical contexts for calcium regulation and stone management.
The dosage of Sus Scrofa Parathyroid Gland must be highly individualized based on the patient's serum calcium levels and the specific condition being treated.
Sus Scrofa Parathyroid Gland is generally not approved for use in pediatric populations unless specifically directed by a specialist in pediatric endocrinology. The risk of disrupting the delicate calcium-phosphate balance in growing children is significant. If prescribed, doses are strictly weight-based and require frequent monitoring of bone density and growth plates.
Patients with significant renal impairment (CrCl < 30 mL/min) require extreme caution. Because the kidneys are the primary site of action for parathyroid hormone and the primary route of elimination for calcium, there is a high risk of hypercalcemia and further renal calcification. Doses should be reduced by at least 50%, and serum calcium must be monitored weekly.
While the liver is involved in the degradation of peptide hormones, no specific dose adjustments are typically required for mild to moderate hepatic impairment. However, patients with severe cirrhosis should be monitored for secondary endocrine disturbances.
Geriatric patients often have undiagnosed reductions in renal function and may be taking other medications that affect calcium levels (e.g., thiazide diuretics). Starting doses should be at the lowest end of the therapeutic range (e.g., 50 mg once daily) with slow titration based on clinical response.
To ensure optimal efficacy and safety, patients should adhere to the following guidelines:
If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to catch up, as this significantly increases the risk of acute hypercalcemia (excessive calcium in the blood).
An overdose of Sus Scrofa Parathyroid Gland can lead to acute hypercalcemia. Symptoms include severe nausea, vomiting, confusion, muscle weakness, and cardiac arrhythmias.
Emergency Measures:
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to rebound hormonal effects.
Patients taking Sus Scrofa Parathyroid Gland most frequently report gastrointestinal and mild metabolic symptoms. These often occur as the body adjusts to changes in calcium levels:
> Warning: Stop taking Sus Scrofa Parathyroid Gland and call your doctor immediately if you experience any of the following serious symptoms. These may indicate life-threatening hypercalcemia or a severe allergic reaction.
Prolonged use of Sus Scrofa Parathyroid Gland requires careful monitoring of bone mineral density (BMD). Because parathyroid hormone stimulates osteoclast activity, chronic over-supplementation can lead to secondary osteoporosis or bone thinning. Additionally, long-term use may suppress the body's own natural parathyroid production, leading to a state of dependency or "glandular atrophy."
No FDA black box warnings are currently issued for Sus Scrofa Parathyroid Gland. However, similar synthetic products (like teriparatide) carry warnings regarding a potential risk of Osteosarcoma (a type of bone cancer) based on animal studies. While this has not been specifically linked to porcine glandular extracts, patients with a history of bone cancer or Paget's disease should avoid this medication.
Report any unusual symptoms, especially persistent bone pain or extreme fatigue, to your healthcare provider immediately. Regular blood tests are the only way to ensure that side effects are not reaching dangerous levels.
Sus Scrofa Parathyroid Gland is a potent biological agent that significantly alters mineral metabolism. It must never be used as a self-prescribed supplement. Patients must have their baseline calcium, phosphate, and vitamin D levels assessed before initiation. Because it contains adrenergic and ACTH-like components, it may also affect blood pressure and stress response pathways.
Currently, there are no FDA black box warnings specifically for Sus Scrofa Parathyroid Gland. However, clinicians often apply the safety precautions used for other parathyroid-modulating agents. This includes avoiding use in patients with increased baseline risk for osteosarcoma, such as those with Paget's disease of the bone or unexplained elevations of alkaline phosphatase.
Because this product is derived from porcine (pig) tissue, it contains foreign proteins. Patients with known allergies to pork or porcine-derived products (such as certain types of insulin or heparin) are at a significantly higher risk for hypersensitivity reactions. Anaphylaxis, though rare, is a possibility and requires immediate emergency intervention.
High levels of calcium (hypercalcemia) typically shorten the QT interval, but the complex mix of catecholamines in this extract could potentially cause unpredictable changes in the cardiac cycle. Patients with long QT syndrome should be monitored via ECG.
Regular laboratory monitoring is mandatory for patients on Sus Scrofa Parathyroid Gland:
This medication may cause dizziness or mild confusion, particularly during the first few days of treatment or after a dose increase. Patients should determine how they react to the medication before driving or operating heavy machinery.
Alcohol should be avoided or strictly limited. Alcohol can interfere with calcium absorption and increase the risk of dehydration, which significantly worsens the potential for kidney stone formation and hypercalcemic complications.
Do not stop taking Sus Scrofa Parathyroid Gland abruptly. Sudden discontinuation can lead to a "rebound" effect where calcium levels drop rapidly (hypocalcemia), causing muscle spasms, tetany, and seizures. A tapering schedule, supervised by a doctor, is necessary to allow the body's own parathyroid glands to resume normal function.
> Important: Discuss all your medical conditions, especially any history of kidney stones, bone disease, or heart problems, with your healthcare provider before starting Sus Scrofa Parathyroid Gland.
Certain medications must NEVER be used in conjunction with Sus Scrofa Parathyroid Gland due to the risk of life-threatening complications:
Sus Scrofa Parathyroid Gland can significantly interfere with several diagnostic tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is essential to prevent dangerous interactions.
Sus Scrofa Parathyroid Gland must NEVER be used in the following circumstances, as the risks far outweigh any potential benefits:
In these cases, a healthcare provider must perform a careful risk-benefit analysis:
Patients who have reacted poorly to other porcine-derived biologics, such as Porcine Insulin, Desiccated Thyroid (Armor Thyroid), or Pancrelipase, should be considered at high risk for cross-sensitivity. The common factor is the presence of porcine proteins and antigens that the human immune system may recognize as foreign.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of bone disease or mineral imbalances, before prescribing Sus Scrofa Parathyroid Gland.
Sus Scrofa Parathyroid Gland is classified as Pregnancy Category C (or equivalent). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown that parathyroid hormone can cross the placental barrier and affect fetal calcium levels, potentially leading to neonatal hypocalcemia or skeletal abnormalities. Its use during pregnancy is generally avoided unless the potential benefit justifies the potential risk to the fetus. It is not recommended for use in fertility treatments.
It is unknown whether the components of Sus Scrofa Parathyroid Gland are excreted in human milk. However, many peptide hormones and proteins do pass into breast milk in small amounts. Because of the potential for serious adverse reactions in nursing infants, including disruptions in their developing mineral metabolism, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of Sus Scrofa Parathyroid Gland in pediatric patients have not been established. Use in children is particularly risky because their bones are still developing. Excessive parathyroid activity can cause premature closure of the epiphyses (growth plates), leading to stunted growth. It should only be used in specialized pediatric endocrine cases where no other alternatives exist.
Clinical studies of glandular extracts often do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are more likely to have:
Elderly patients should start at the lowest possible dose.
In patients with mild to moderate renal impairment, the clearance of the active components is reduced, and the risk of mineral accumulation is high.
No specific dosage adjustments are provided for patients with hepatic impairment. However, since the liver produces many of the transport proteins for hormones, patients with Child-Pugh Class B or C liver disease should be monitored for signs of increased free (unbound) hormone activity, which may intensify side effects.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring to ensure safety.
Sus Scrofa Parathyroid Gland acts as a multi-component biological modulator. Its primary active constituent, porcine parathyroid hormone (pPTH), binds to the G-protein coupled PTH1 receptor located on the surface of osteoblasts in bone and tubular cells in the kidney.
| Parameter | Value |
|---|---|
| Bioavailability | 15-25% (Oral, highly variable) |
| Protein Binding | 70-80% (Primarily to albumin) |
| Half-life | 15-45 minutes (Active peptides) |
| Tmax | 1-2 hours (Oral) |
| Metabolism | Hepatic endopeptidases |
| Excretion | Renal 90%, Fecal 10% |
Sus Scrofa Parathyroid Gland is categorized as a Calculi Dissolution Agent [EPC]. It is related to synthetic agents like Teriparatide (Forteo) and Abaloparatide (Tymlos), though it differs by being a full-spectrum glandular extract rather than a single synthetic peptide fragment.
Common questions about Parathyroid Cord
Sus Scrofa Parathyroid Gland is primarily used as a calculi dissolution agent to help break down and prevent kidney and bladder stones. It works by regulating calcium and phosphate levels in the blood and urine, using its natural acidifying and chelating properties. Additionally, it may be used in integrative medicine to support patients with parathyroid insufficiency or other endocrine imbalances. Because it contains multiple biological components like ACTH and catecholamines, it is sometimes used for broader metabolic support. Always use this medication under the strict supervision of a healthcare provider to ensure it is appropriate for your specific mineral balance.
The most common side effects include gastrointestinal issues such as nausea, constipation, and abdominal bloating. These occur as the body adjusts to changes in calcium levels and the biological proteins in the extract. Some patients also report mild headaches, increased thirst, and a frequent need to urinate. Dry mouth is another common side effect, linked to the adrenergic components of the medication. Most of these symptoms are mild and temporary, but you should report any persistent discomfort to your doctor. If you experience severe vomiting or confusion, seek medical help immediately as these could be signs of high calcium.
It is strongly recommended to avoid or significantly limit alcohol consumption while taking Sus Scrofa Parathyroid Gland. Alcohol acts as a diuretic and can lead to dehydration, which increases the risk of developing new kidney stones and complicates the dissolution of existing ones. Furthermore, alcohol can interfere with the absorption of calcium and the metabolic processing of the glandular extract. Combining alcohol with this medication may also increase the risk of gastrointestinal irritation and dizziness. For the best therapeutic results and to ensure your safety, discuss your alcohol intake with your healthcare provider.
Sus Scrofa Parathyroid Gland is generally not recommended during pregnancy. It is classified as Pregnancy Category C, meaning there is a lack of definitive human studies and animal data suggests potential risks to the fetus. The medication significantly alters calcium and phosphate metabolism, which are critical for the developing skeletal system of the baby. Using this drug during pregnancy could lead to abnormal calcium levels in both the mother and the newborn. If you are pregnant or planning to become pregnant, you must discuss alternative treatments with your doctor. Breastfeeding is also discouraged while using this porcine-derived product.
The timeframe for seeing results with Sus Scrofa Parathyroid Gland depends on the condition being treated. For acute mineral regulation, changes in urinary phosphate and blood calcium can be detected within a few hours of the first dose. However, for the dissolution of kidney stones (calculi), the process is much slower and typically takes several weeks to months of consistent use. Patients are often monitored via ultrasound or X-ray every 4 to 8 weeks to track the reduction in stone size. It is important to continue the medication as prescribed, even if you do not feel immediate relief, as stone dissolution is a gradual biochemical process.
No, you should never stop taking Sus Scrofa Parathyroid Gland suddenly without consulting your doctor. Because this medication provides external hormonal support, your body's own parathyroid glands may have reduced their natural production. Abruptly stopping the drug can cause a 'rebound' effect, leading to a dangerous drop in blood calcium levels known as hypocalcemia. Symptoms of this can include muscle cramps, tingling in the fingers, and in severe cases, seizures or heart rhythm problems. Your healthcare provider will provide a tapering schedule to slowly reduce the dose, allowing your glands to safely resume their normal function.
If you miss a dose of Sus Scrofa Parathyroid Gland, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose entirely and return to your regular schedule. Do not take two doses at once to make up for the one you missed, as this increases the risk of acute hypercalcemia and other side effects. To help prevent missed doses, try taking the medication at the same time every day, perhaps using a pill organizer or a phone reminder. If you miss multiple doses in a row, contact your healthcare provider for specific instructions on how to restart.
Weight gain is not a commonly reported side effect of Sus Scrofa Parathyroid Gland. However, the medication does contain ACTH-like components which, in theory, could affect cortisol levels and lead to fluid retention or changes in fat distribution if used in very high doses over a long period. Most patients do not experience significant weight changes. If you notice rapid weight gain, swelling in your ankles, or a 'puffy' face, you should contact your doctor, as these could be signs of an endocrine imbalance or a reaction to the medication. Maintaining a healthy diet and staying hydrated is recommended during treatment.
Sus Scrofa Parathyroid Gland has several significant drug interactions, so it must be used cautiously with other medications. It should never be taken with Digoxin, as it can lead to dangerous heart rhythms. It also interacts with thiazide diuretics, high-dose Vitamin D, and bisphosphonates, all of which affect calcium levels. Even common antacids and calcium supplements can interfere with how this drug works. Because of these complexities, it is vital that you provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking before starting this treatment.
Sus Scrofa Parathyroid Gland is a biological extract rather than a simple chemical drug, so the concept of a 'generic' is slightly different. While there are various brands and manufacturers of porcine parathyroid glandulars, they are not always bioequivalent (identical in effect). Different extraction processes can result in varying levels of active hormones and co-factors. In the United States, these are often marketed as 'glandular concentrates' or within complex homeopathic formulations rather than as standard generic prescriptions. Always stick with the specific brand or preparation recommended by your healthcare provider to ensure consistent dosing and results.